SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Vistagen Therapeutics, Inc. Common Stock and Sets a Lead Plaintiff Deadline of March 16, 2026

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. due to allegations of misleading statements regarding its Phase 3 PALISADE-3 trial for fasedienol, which did not meet its primary endpoint [1][2][3]. Group 1: Lawsuit Details - The lawsuit, Dan Eller v. Vistagen Therapeutics, Inc., was initiated in the United States District Court for the Northern District of California [1]. - The complaint alleges that Vistagen provided overly positive statements while concealing material adverse facts about the Phase 3 trial of fasedienol [2]. Group 2: Trial Results - On December 17, 2025, Vistagen announced that the PALISADE-3 Phase 3 study did not show a statistically significant improvement on the primary endpoint, with no treatment difference between fasedienol and placebo for secondary endpoints [3]. Group 3: Stock Price Impact - Following the announcement of the trial results, Vistagen's stock price plummeted from $4.36 per share on December 16, 2025, to $0.86 per share on December 17, 2025, marking a decline of over 80% [4]. Group 4: Legal Representation - Levi & Korsinsky, LLP, the law firm representing the plaintiffs, has a strong track record in securities litigation and encourages affected shareholders to step forward before the March 16, 2026 deadline [4][5].